Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909953 | 0.92 | ABCG2 (0.37) | ABCG2PDE5ATDP1L3MBTL1DHODH | |
| SCHEMBL29909200 | 0.89 | EGFR (0.35) | ABCG2PDE5A | |
| SCHEMBL29909024 | 0.89 | ABCG2 (0.37) | ABCG2PDE5ADHODH | |
| SCHEMBL29909829 | 0.86 | ABCG2 (0.36) | ABCG2PDE5ADHODH | |
| SCHEMBL29909687 | 0.85 | ABCG2 (0.37) | ABCG2PDE5ADHODH | |
| SCHEMBL29909643 | 0.85 | ABCG2 (0.37) | ABCG2PDE5ADHODH | |
| SCHEMBL29909406 | 0.85 | ABCG2 (0.36) | ABCG2PDE5ADHODH | |
| SCHEMBL29909204 | 0.84 | ABCG2 (0.35) | ABCG2PDE5ADHODH | |
| SCHEMBL29909758 | 0.84 | ABCG2 (0.37) | ABCG2PDE5ADHODH | |
| SCHEMBL29909441 | 0.83 | ABCG2 (0.34) | ABCG2PDE5ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | ABCG2 4216/4885PDE5A 1924/4885TDP1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.